EZH2 and epithelioid sarcoma: Most new drugs targeting EZH2 are still in the preclinical phase or phase 1/2 of clinical trials, but tazemetostat was approved for the treatment of epithelioid sarcoma (ES) and preliminarily showed promising effects on follicular lymphoma (FL) (Straining and Eighmy, 2022).